INTELIPHAGE

Our mission is to deliver evidence-driven, personalized therapies that combat difficult-to-treat and antimicrobial-resistant infections

Restoring hope for patients with no remaining options and broadening access to life-changing care.

Our mission

Inteliphage

To deliver evidence-driven, personalized therapies that combat difficult-to-treat and resistant infections. We strive to restore hope for patients with no remaining options and broaden access to life-changing care

Antimicrobial Resistance (AMR) : AMR is a growing global crisis, already claiming 1.3 million lives annually, a figure projected to reach 10 million by 2050. As antibiotics lose effectiveness against resistant infections, patients face life-threatening conditions with no treatment options, threatening global health and economies.

Personalized Therapy: We address difficult-to-treat and resistant infections with an innovative, evidence-driven approach to personalized phage-antibiotic therapy. By combining selective bacteriophages, advanced diagnostics, and decision-support tools, we deliver precise, effective treatments tailored to each patient. Our holistic solution restores hope for those battling difficult-to-treat and resistant bacterial infections, and expands access to transformative care.

The European Innovation Council’s Acceleration Fund has awarded Inteliphage €1.8M in 2023
Inteliphage named most innovative start-up in Life Sciences in Europe at tenth edition of BioFIT (2021)

INVEST IN TRANSFORMING THE FIGHT AGAINST ANTIMICROBIAL RESISTANCE

Our daily life

Latest news

Don’t miss any important events or news about Inteliphage.